RxDoctor Payments Data

Anna Naeva, NP

Psychiatric/Mental Health · Hanover, MANPI 1710564927

Payments from drug & device makers

$2,644in general payments, 2019–2025

Across 95 payments — averaging $27.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$952
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$772
  • Johnson & Johnson$386
  • E.r. Squibb & Sons, L.L.C.$125
  • Otsuka America Pharmaceutical, Inc.$123
  • Neurocrine Biosciences, Inc.$92
  • plus $195 from 6 others

What the payments were for

  • Food & beverage$2,59798%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,644 in reported general payments places this provider in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$15,831
Medicare patients
37
Services billed
150

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl40$46,098
VraylarCariprazine Hcl13$12,399
Trazodone Hcl50$1,355
Aripiprazole22$1,185
Venlafaxine Hcl ErVenlafaxine Hcl57$1,040
Atomoxetine Hcl12$1,018
Ziprasidone Hcl17$766
Quetiapine Fumarate58$746
Duloxetine Hcl24$636
Prazosin Hcl34$625
Lamotrigine83$597
Olanzapine31$443
Divalproex Sodium18$401
Buspirone Hcl25$383
Risperidone34$382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$386$46,09840 claims
AbbVieVraylar$952$12,39913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Hanover

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →